Search Result

Results for "

Fc receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Fc Receptor (FcR) (17) ADC Antibody (1) Apoptosis (15) BMX Kinase (2) Btk (5) c-Fms (1) Caspase (3) CD19 (1) CD20 (1) CD3 (4) CD38 (1) CD44 (1) Complement System (1) CTLA-4 (1) Drug Derivative (1) EGFR (2) Endogenous Metabolite (1) Ephrin Receptor (1) Estrogen Receptor/ERR (2) FGFR (1) G Protein-coupled Receptor Kinase (GRK) (1) Influenza Virus (1) Insulin Receptor (1) Interleukin Related (9) Isotope-Labeled Compounds (2) Mas-related G-protein-coupled Receptor (MRGPR) (1) NF-κB (1) Opioid Receptor (1) Orexin Receptor (OX Receptor) (1) PD-1/PD-L1 (3) Phosphodiesterase (PDE) (1) Reference Standards (2) RSV (1) Slit Proteins (1) Syk (1) TGF-beta/Smad (1) TGF-β Receptor (1) Tie (1) TNF Receptor (17) Toll-like Receptor (TLR) (3) Transmembrane Glycoprotein (2) VEGFR (1) Wnt (1) β-glucuronidase (1)
By Research Areas:	Cancer (49) Cardiovascular Disease (6) Endocrinology (2) Infection (6) Inflammation/Immunology (50) Metabolic Disease (5) Neurological Disease (3)

By Targets:

Fc Receptor (FcR) (17)

ADC Antibody (1)

Apoptosis (15)

BMX Kinase (2)

Btk (5)

c-Fms (1)

Caspase (3)

CD19 (1)

CD20 (1)

CD3 (4)

CD38 (1)

CD44 (1)

Complement System (1)

CTLA-4 (1)

Drug Derivative (1)

EGFR (2)

Endogenous Metabolite (1)

Ephrin Receptor (1)

Estrogen Receptor/ERR (2)

FGFR (1)

G Protein-coupled Receptor Kinase (GRK) (1)

Influenza Virus (1)

Insulin Receptor (1)

Interleukin Related (9)

Isotope-Labeled Compounds (2)

Mas-related G-protein-coupled Receptor (MRGPR) (1)

NF-κB (1)

Opioid Receptor (1)

Orexin Receptor (OX Receptor) (1)

PD-1/PD-L1 (3)

Phosphodiesterase (PDE) (1)

Reference Standards (2)

RSV (1)

Slit Proteins (1)

Syk (1)

TGF-beta/Smad (1)

TGF-β Receptor (1)

Tie (1)

TNF Receptor (17)

Toll-like Receptor (TLR) (3)

Transmembrane Glycoprotein (2)

VEGFR (1)

Wnt (1)

β-glucuronidase (1)

By Research Areas:

Cancer (49)

Cardiovascular Disease (6)

Endocrinology (2)

Infection (6)

Inflammation/Immunology (50)

Metabolic Disease (5)

Neurological Disease (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Fc Receptor (FcR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9977

Amivantamab 3 Publications Verification JNJ-61186372	EGFR	Inflammation/Immunology Cancer
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-P99930

Efruxifermin 2 Publications Verification AKR-001; AMG-876	FGFR	Metabolic Disease
Efruxifermin is an *Fc-FGF21* fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

HY-P9950

Omalizumab 1 Publications Verification Olizumab; rhuMab-E25; IGE25; RG-3648	Interleukin Related	Inflammation/Immunology Cancer
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.

HY-P99590

Sotatercept 2 Publications Verification ACE-011; MK-7962	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

HY-B0723

Ospemifene 2 Publications Verification Fc-1271a	Estrogen Receptor/ERR Caspase	Neurological Disease Endocrinology Cancer
Ospemifene (FC-1271a) is an orally active and non-estrogenic selective estrogen receptor modulator (SERM) with K_i values of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene inhibits caspase-3 activity. Ospemifene inhibits neuronal degeneration, prevents bone loss, and increases vaginal weight and vaginal epithelial height. Ospemifene has anticancer activity against breast cancer .

HY-147305

Efgartigimod alfa ARGX-113	Fc Receptor (FcR)	Inflammation/Immunology
Efgartigimod alfa (ARGX-113) is a reversibility, humanized ^Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research .

HY-13690

Mitotane 5 Publications Verification 2,4′-DDD; o,p'-DDD	Apoptosis	Cancer
Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .

HY-P9954

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P9979

Rozanolixizumab 1 Publications Verification UCB7665	TNF Receptor	Inflammation/Immunology
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P990715

Ozekibart INBRX-109	TNF Receptor	Cancer
Ozekibart (INBRX-109) is a DR5 agonist and antitumor agent with a human DR5 IC₅₀ of 0.17 nmol/L and human DR5 K_a of 0.11 nmol/L. Ozekibart can be used for the research of unresectable/metastatic chondrosarcoma .

HY-P991155

Ramantamig JNJ-79635322; JNJ-5322	CD3 TNF Receptor	Cancer
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-P99300

Ligelizumab 1 Publications Verification QGE 031; Anti-IGHE Recombinant Antibody	Fc Receptor (FcR)	Inflammation/Immunology
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .

HY-NP006

Protein A 1 Publications Verification SPA	Endogenous Metabolite Apoptosis	Inflammation/Immunology
Protein A (SPA) is an immunoglobulin (Ig)-binding protein that exists on the bacterial surface and can be freely secreted into the extracellular environment. Protein A blocks opsonophagocytosis and induces B cell apoptosis in vitro by binding to the Fc region of antibodies and the Fab region of B cell receptors. Protein A can form toxic immune complexes with IgG, thereby inducing leukocyte necrosis. Protein A contributes to the virulence expression of Staphylococcus aureus. Protein A triggers allergic reactions in IgG-pretreated mouse models. Protein A can be used in studies related to immune system diseases .

HY-15322

PRT062607 4 Publications Verification P505-15; PRT-2607; BIIB-057	Syk Apoptosis Caspase	Inflammation/Immunology Cancer
PRT062607 (P505-15; PRT-2607) is an orally active ATP-competitive Syk inhibitor with an IC₅₀ value of 1 nM, and exhibits at least 80-fold selectivity over other kinases. PRT062607 blocks B cell antigen receptor-mediated activation, Fcε receptor 1-mediated basophil degranulation and microglial phagocytosis, and induces caspase-dependent apoptosis and microglial death. PRT062607 inhibits tumor growth and peripheral nerve injury-induced mechanical allodynia, and prevents neuronal loss. PRT062607 can be used in research related to rheumatoid arthritis, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, neurodegenerative diseases and neuropathic pain .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	TNF Receptor	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P99934

Eftozanermin alfa 1 Publications Verification ABBV-621	Apoptosis Caspase TNF Receptor	Cancer
Eftozanermin alfa (ABBV-621) is a tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa is a fusion protein consisting of a mutant immunoglobulin G1-Fc linked to 2 single-chain trimers of TRAIL. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors (DR4 receptor and DR5 receptor) with K_ds of 780 nM and 635 nM. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Inflammation/Immunology Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .

HY-P99332

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Apoptosis	Inflammation/Immunology Cancer
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-109010

Poseltinib 2 Publications Verification HM71224; LY3337641	Btk BMX Kinase Toll-like Receptor (TLR)	Metabolic Disease
Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Bruton tyrosine kinase (BTK) inhibitor. With an IC₅₀ of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR). Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis .

HY-P99665

Insulin efsitora alfa LY-3209590	Insulin Receptor	Metabolic Disease
Insulin efsitora alfa (LY-3209590) is a selective agonist of *insulin receptor* (IR)**. Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99804

Clesrovimab 3 Publications Verification MK1654	RSV	Infection
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding K_D values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .

HY-P99667

Ipafricept 4 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-P99546

Trebananib 2xCon4C; AMG 386	Tie	Cardiovascular Disease Cancer
Trebananib (2xCon4C) is an Fc fusion peptibody. Trebananib exerts its effects by blocking the binding of angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) to the TIE2 receptor. Trebananib has anti-angiogenic and anti-tumor activities .

HY-P99470

Benufutamab GEN1029	TNF Receptor Apoptosis	Cancer
Benufutamab (GEN1029) is a *death receptor* 5 (DR5)**-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .

HY-P99008

Atibuclimab 2 Publications Verification IC14	Toll-like Receptor (TLR)	Infection Neurological Disease Inflammation/Immunology
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .

HY-P99661

Inbakicept 2 Publications Verification	Interleukin Related	Cancer
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .

HY-P99529

Valziflocept BAX1810; TAK-752; SM101	Fc Receptor (FcR)	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE) .

HY-P991055

Forimtamig RG-6234; RO-7425781	CD3	Inflammation/Immunology
Forimtamig (RG-6324) is a GPRC5DxCD3 T-cell-engaging bispecific antibody. Forimtamig has a 2 + 1 format, comprising two high-affinity GPRC5D binding moieties and one CD3 binder. Forimtamig further features a P329G LALA mutated Fc domain that inhibits Fcγ receptor and C1q binding, yet retains binding to the neonatal Fc receptor. The isotype control for Forimtamig can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990256

Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9)	CTLA-4	Inflammation/Immunology Cancer
Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) is a mouse-derived IgG2a κ type antibody inhibitor targeting to mouse CTLA-4/CD152. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) can be used for the researches of cancer and immunology, such as colon .

HY-P9977A

Amivantamab (FUT8-KO)	EGFR	Cancer
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-P99125

Anti-Mouse CD16/CD32 Antibody (2.4G2)	Fc Receptor (FcR)	Cardiovascular Disease Inflammation/Immunology
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders .

HY-139690

CCG258747 1 Publications Verification	Opioid Receptor G Protein-coupled Receptor Kinase (GRK) Mas-related G-protein-coupled Receptor (MRGPR)	Cardiovascular Disease Inflammation/Immunology
CCG258747 is a selective GRK2 inhibitor (IC₅₀ = 18 nM) with high selectivity over GRK1, GRK5, PKA, and ROCK1 (518, 83, > 5500, and > 550-fold, respectively). CCG258747 also blocks the internalization of the µ-opioid receptor (MOR). CCG258747 attenuates IgE mediated anaphylaxis by inhibiting GRK2 and FcεRI signaling pathway but activates mast cells via MRGPRX2 and MRGPRB2. CCG258747 can be used to study diseases related to overexpression of GRK2 (such as heart failure, opioid tolerance) .

HY-P990172

Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.

HY-P990171

Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (K_d = 0.5 pM), VEGF-B (K_d = 8 pM), VEGF-C, and PlGF (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .

HY-P99381

XmAb 5592 1 Publications Verification	Transmembrane Glycoprotein	Cancer
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .

HY-P991086

MGD010 PRV-3279	Fc Receptor (FcR)	Inflammation/Immunology
MGD010 (PRV-3279) is a bispecific antibody targeting CD32B (FcγRIIb) and CD79B. MGD010 transmits negative signals by simultaneously co-linking CD32B (FcγRIIb) with CD79B, a component of the B-cell receptor (BCR), thereby inhibiting activated B cells. MGD010 can be used in research related to autoimmune diseases .

HY-P990067

Evunzekibart ATOR-1017	TNF Receptor	Cancer
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

HY-P990291

Anti-Mouse CD16.2 Antibody (9E9)	Fc Receptor (FcR)	Inflammation/Immunology Cancer
Anti-Mouse CD16.2 Antibody (9E9) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD16.2. Anti-Mouse CD16.2 Antibody (9E9) reacts with mouse CD16.2, also known as FcγRIV (Fc receptor, IgG, low affinity IV). Anti-Mouse CD16.2 Antibody (9E9) inhibits cellular CD16.2 expression and signaling and blocks FcγRIV. Anti-Mouse CD16.2 Antibody (9E9) can be used for the researches of cancer, inflammation and immunology, such as CT26 tumor and lung inflammation .

HY-N16039

TAN-1030A	β-glucuronidase	Inflammation/Immunology
TAN-1030A is an indolocarbazole alkaloid with macrophage-activating properties. TAN-1030A induces spreading of a murine macrophage cell line, Mm 1, and augmentes the phagocytic activity, Fc gamma receptor expression and β-glucuronidase activity of murine macrophage cell lines, Mm 1 and J774A.1. TAN-1030A can activate macrophage functions in mice .

HY-P991214

Tucotuzumab celmoleukin EMD 273066; huKS-IL2	Interleukin Related	Cancer
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer .

HY-P990863

Anti-CD32/FcγRIIA Antibody (IV.3)	Fc Receptor (FcR)	Infection Inflammation/Immunology
Anti-CD32/FcγRIIA Antibody (IV.3) is a kind of mouse IgG2b chimeric antibody inhibitor, targeting to human CD32/FcγRIIA. Anti-CD32/FcγRIIA Antibody (IV.3) can block Fc receptor IIA. Anti-CD32/FcγRIIA Antibody (IV.3) can be used for the researches of inflammation and infection, such as arthritis and E. coli infection .

HY-W078239

EPHA4 antagonist-1	Ephrin Receptor	Cancer
EPHA4 antagonist-1 (Compound 2) is an EphA4 receptor antagonist. EPHA4 antagonist-1 is also an EphA2 receptor antagonist. EPHA4 antagonist-1 inhibits ephrin-A5 AP binding to EphA4 Fc receptor, with an IC₅₀ of 10 μM .

HY-P990269

Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)	TNF Receptor	Inflammation/Immunology Cancer
Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG2a. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.

HY-P99487

Briobacept BR 3Fc	ADC Antibody	Inflammation/Immunology
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) .

HY-P990720

Elritercept KER-050	TGF-beta/Smad	Inflammation/Immunology
Elritercept (KER-050) is a recombinant fusion protein comprising a modified activin receptor type IIA extracellular domain fused to a human IgG1 Fc. Elritercept inhibits activin A and other select TGF-β superfamily ligands .

HY-P991074

GMA-161	Fc Receptor (FcR)	Inflammation/Immunology
GMA-161 is a humanized IgG1 antibody that targets *Fcγ receptor* III (CD16)**. GMA-161 has the potential for the study of autoimmune disorders. The isotype control for GMA-161 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Type

HY-NP006

Protein A

1 Publications Verification

SPA

Biochemical Assay Reagents

Protein A (SPA) is an immunoglobulin (Ig)-binding protein that exists on the bacterial surface and can be freely secreted into the extracellular environment. Protein A blocks opsonophagocytosis and induces B cell apoptosis in vitro by binding to the Fc region of antibodies and the Fab region of B cell receptors. Protein A can form toxic immune complexes with IgG, thereby inducing leukocyte necrosis. Protein A contributes to the virulence expression of Staphylococcus aureus. Protein A triggers allergic reactions in IgG-pretreated mouse models. Protein A can be used in studies related to immune system diseases .

Cat. No.	Product Name	Target	Research Area

HY-P10544

Humanized anti-tac (HAT) binding peptide	Interleukin Related	Others
Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonal antibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonal antibodies .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9977

Amivantamab 3 Publications Verification JNJ-61186372	EGFR	Inflammation/Immunology Cancer
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-P99930

Efruxifermin 2 Publications Verification AKR-001; AMG-876	FGFR	Metabolic Disease
Efruxifermin is an *Fc-FGF21* fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

HY-P9950

Omalizumab 1 Publications Verification Olizumab; rhuMab-E25; IGE25; RG-3648	Interleukin Related	Inflammation/Immunology Cancer
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.

HY-P99590

Sotatercept 2 Publications Verification ACE-011; MK-7962	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

HY-147305

Efgartigimod alfa ARGX-113	Fc Receptor (FcR)	Inflammation/Immunology
Efgartigimod alfa (ARGX-113) is a reversibility, humanized ^Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research .

HY-P9954

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P9979

Rozanolixizumab 1 Publications Verification UCB7665	TNF Receptor	Inflammation/Immunology
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P990715

Ozekibart INBRX-109	TNF Receptor	Cancer
Ozekibart (INBRX-109) is a DR5 agonist and antitumor agent with a human DR5 IC₅₀ of 0.17 nmol/L and human DR5 K_a of 0.11 nmol/L. Ozekibart can be used for the research of unresectable/metastatic chondrosarcoma .

HY-P991155

Ramantamig JNJ-79635322; JNJ-5322	CD3 TNF Receptor	Cancer
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-P99300

Ligelizumab 1 Publications Verification QGE 031; Anti-IGHE Recombinant Antibody	Fc Receptor (FcR)	Inflammation/Immunology
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	TNF Receptor	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P99934

Eftozanermin alfa 1 Publications Verification ABBV-621	Apoptosis Caspase TNF Receptor	Cancer
Eftozanermin alfa (ABBV-621) is a tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa is a fusion protein consisting of a mutant immunoglobulin G1-Fc linked to 2 single-chain trimers of TRAIL. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors (DR4 receptor and DR5 receptor) with K_ds of 780 nM and 635 nM. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Inflammation/Immunology Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .

HY-P99332

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Apoptosis	Inflammation/Immunology Cancer
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-P99665

Insulin efsitora alfa LY-3209590	Insulin Receptor	Metabolic Disease
Insulin efsitora alfa (LY-3209590) is a selective agonist of *insulin receptor* (IR)**. Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99804

Clesrovimab 3 Publications Verification MK1654	RSV	Infection
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding K_D values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .

HY-P99667

Ipafricept 4 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-P99546

Trebananib 2xCon4C; AMG 386	Tie	Cardiovascular Disease Cancer
Trebananib (2xCon4C) is an Fc fusion peptibody. Trebananib exerts its effects by blocking the binding of angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) to the TIE2 receptor. Trebananib has anti-angiogenic and anti-tumor activities .

HY-P99470

Benufutamab GEN1029	TNF Receptor Apoptosis	Cancer
Benufutamab (GEN1029) is a *death receptor* 5 (DR5)**-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .

HY-P99008

Atibuclimab 2 Publications Verification IC14	Toll-like Receptor (TLR)	Infection Neurological Disease Inflammation/Immunology
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .

HY-P99661

Inbakicept 2 Publications Verification	Interleukin Related	Cancer
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .

HY-P99529

Valziflocept BAX1810; TAK-752; SM101	Fc Receptor (FcR)	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE) .

HY-P991055

Forimtamig RG-6234; RO-7425781	CD3	Inflammation/Immunology
Forimtamig (RG-6324) is a GPRC5DxCD3 T-cell-engaging bispecific antibody. Forimtamig has a 2 + 1 format, comprising two high-affinity GPRC5D binding moieties and one CD3 binder. Forimtamig further features a P329G LALA mutated Fc domain that inhibits Fcγ receptor and C1q binding, yet retains binding to the neonatal Fc receptor. The isotype control for Forimtamig can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990256

Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9)	CTLA-4	Inflammation/Immunology Cancer
Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) is a mouse-derived IgG2a κ type antibody inhibitor targeting to mouse CTLA-4/CD152. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) can be used for the researches of cancer and immunology, such as colon .

HY-P9977A

Amivantamab (FUT8-KO)	EGFR	Cancer
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-P99125

Anti-Mouse CD16/CD32 Antibody (2.4G2)	Fc Receptor (FcR)	Cardiovascular Disease Inflammation/Immunology
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders .

HY-P990172

Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.

HY-P990171

Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (K_d = 0.5 pM), VEGF-B (K_d = 8 pM), VEGF-C, and PlGF (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .

HY-P99381

XmAb 5592 1 Publications Verification	Transmembrane Glycoprotein	Cancer
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .

HY-P99983

Mouse IgG1 (D265A) kappa, Isotype Control	Inhibitory Antibodies	Inflammation/Immunology
Mouse IgG1 (D265A) kappa, Isotype Control is a mouse IgG1(D265A)κ isotype control with a D265A mutation and inactivity against mouse Fc gamma receptors (FcγR1, FcγR2, FcγR3, FcγR4) .

HY-P991086

MGD010 PRV-3279	Fc Receptor (FcR)	Inflammation/Immunology
MGD010 (PRV-3279) is a bispecific antibody targeting CD32B (FcγRIIb) and CD79B. MGD010 transmits negative signals by simultaneously co-linking CD32B (FcγRIIb) with CD79B, a component of the B-cell receptor (BCR), thereby inhibiting activated B cells. MGD010 can be used in research related to autoimmune diseases .

HY-P990067

Evunzekibart ATOR-1017	TNF Receptor	Cancer
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

HY-P990291

Anti-Mouse CD16.2 Antibody (9E9)	Fc Receptor (FcR)	Inflammation/Immunology Cancer
Anti-Mouse CD16.2 Antibody (9E9) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD16.2. Anti-Mouse CD16.2 Antibody (9E9) reacts with mouse CD16.2, also known as FcγRIV (Fc receptor, IgG, low affinity IV). Anti-Mouse CD16.2 Antibody (9E9) inhibits cellular CD16.2 expression and signaling and blocks FcγRIV. Anti-Mouse CD16.2 Antibody (9E9) can be used for the researches of cancer, inflammation and immunology, such as CT26 tumor and lung inflammation .

HY-P991214

Tucotuzumab celmoleukin EMD 273066; huKS-IL2	Interleukin Related	Cancer
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer .

HY-P990863

Anti-CD32/FcγRIIA Antibody (IV.3)	Fc Receptor (FcR)	Infection Inflammation/Immunology
Anti-CD32/FcγRIIA Antibody (IV.3) is a kind of mouse IgG2b chimeric antibody inhibitor, targeting to human CD32/FcγRIIA. Anti-CD32/FcγRIIA Antibody (IV.3) can block Fc receptor IIA. Anti-CD32/FcγRIIA Antibody (IV.3) can be used for the researches of inflammation and infection, such as arthritis and E. coli infection .

HY-P990269

Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)	TNF Receptor	Inflammation/Immunology Cancer
Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG2a. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.

HY-P99487

Briobacept BR 3Fc	ADC Antibody	Inflammation/Immunology
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) .

HY-P990720

Elritercept KER-050	TGF-beta/Smad	Inflammation/Immunology
Elritercept (KER-050) is a recombinant fusion protein comprising a modified activin receptor type IIA extracellular domain fused to a human IgG1 Fc. Elritercept inhibits activin A and other select TGF-β superfamily ligands .

HY-P991074

GMA-161	Fc Receptor (FcR)	Inflammation/Immunology
GMA-161 is a humanized IgG1 antibody that targets *Fcγ receptor* III (CD16)**. GMA-161 has the potential for the study of autoimmune disorders. The isotype control for GMA-161 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990959

Lesigercept	Apoptosis	Inflammation/Immunology
Lesigercept is a recombinant fusion protein comprising an *FcERI (IgE Fc receptor* subunit alpha)** fused to a human IgG4 Fc .

HY-P99543

Tulinercept OPRX-106; PRX-106; TNFR-Fc	TNF Receptor	Cancer
Tulinercept (OPRX-106) is a recombinant TNF receptor fusion protein fused to an IgG1 Fc domain .

HY-P99692

Lenercept p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1	TNF Receptor	Inflammation/Immunology
Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble *TNF-receptor* (p55) linked to the Fc portion of human IgG1 .

HY-P991677

Efmirenpase alfa INZ-701	Phosphodiesterase (PDE)	Cardiovascular Disease Endocrinology
Efmirenpase alfa is an *Fc-ENPP1* fusion protein (human IgG1 Fc domain linked to a modified human ENPP1). Efmirenpase alfa has prolonged half-life and enhanced receptor affinity compared with native human ENPP1. Efmirenpase alfa can be used as an enzyme replacement therapy for ENPP1 deficiency such as arterial calcification and hypophosphatemic rickets research .

HY-P990719

Efbalropendekin alfa XmAb24306	Interleukin Related	Inflammation/Immunology Cancer
Efbalropendekin Alfa (XmAb24306) is an IL-15/IL-15 receptor alpha complex fused to a heterodimeric Fc domain (IL15/IL15Rα-Fc). Efbalropendekin Alfa increases direct and antibody-dependent cellular cytotoxicity (ADCC)-mediated human natural killer (NK) cell cytotoxicity in vitro .

HY-P991514

MIL62	CD20	Cancer
MIL62 is an anti-CD20 monoclonal antibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .

HY-P99913

Eflapegrastim	c-Fms	Inflammation/Immunology Cancer
Eflapegrastim is a composite protein consisting of a genetically modified granulocyte-colony stimulating factor (GCSF) molecule linked via a chemical bond to an IgG4 Fc fragment (LAPS-carrier). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N16039

TAN-1030A	Alkaloids Microorganisms Indole Alkaloids Source Classification	β-glucuronidase
TAN-1030A is an indolocarbazole alkaloid with macrophage-activating properties. TAN-1030A induces spreading of a murine macrophage cell line, Mm 1, and augmentes the phagocytic activity, Fc gamma receptor expression and β-glucuronidase activity of murine macrophage cell lines, Mm 1 and J774A.1. TAN-1030A can activate macrophage functions in mice .

HY-N11725

Phlorofucofuroeckol A	Structural Classification Microorganisms Phenols Polyphenols Source Classification	Fc Receptor (FcR)
Phlorofucofuroeckol A is a FcεRI inhibitor with low cytotoxicity toward basophilic leukemia cells. Phlorofucofuroeckol A suppresses binding activity between IgE and FcεRI receptor. Phlorofucofuroeckol A inhibits histamine release from basophilic leukemia cells stimulated by IgE/anti-IgE or calcium ionophore A23187 (HY-N6687). Phlorofucofuroeckol A inhibits β-hexosaminidase release from basophilic leukemia cells stimulated by IgE/DNP-BSA. Phlorofucofuroeckol A can be used for the research of allergy disease .

Cat. No.	Product Name	Chemical Structure

HY-13690S1

Mitotane-13C6

Mitotane- ¹³C₆ is the ¹³C labeled Mitotane . Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .

HY-13690S3

Mitotane-13C12

Mitotane- ¹³C₁₂ (2,4′-DDD- ¹³C₁₂) is ¹³C labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .

HY-B0723S2

Ospemifene-d5
Ospemifene-d₅ (FC-1271a-d₅) is deuterium labeled Ospemifene. Ospemifene is a non-estrogen selective estrogen receptor modulator (SERM), with K_is of 380 and 410 nM for *estrogen receptor* α (ERα) and ERβ**, respectively. Ospemifene can be used for the research of vaginal atrophy and breast cancer .

HY-13690S2

Mitotane-d8

Mitotane-d₈ is the deuterium labeled Mitotane . Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Fc receptors

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products